The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer by Meiko Nishimura et al.
1 3
Cancer Chemother Pharmacol (2016) 77:1165–1170
DOI 10.1007/s00280-016-3026-6
ORIGINAL ARTICLE
The combination of HLA‑B*15:01 and DRB1*15:01 is associated 
with gemcitabine plus erlotinib‑induced interstitial lung disease 
in patients with advanced pancreatic cancer
Meiko Nishimura1 · Masanori Toyoda1 · Kei Takenaka1 · Yoshinori Imamura1 · 
Naoko Chayahara1 · Naomi Kiyota1 · Toru Mukohara1,2 · Takeshi Kotake3,5 · 
Akihito Tsuji3,6 · Kosuke Saito4 · Yoshiro Saito4 · Hironobu Minami1,2 
Received: 1 March 2016 / Accepted: 28 March 2016 / Published online: 21 April 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
at 100 mg/day). We compared the frequencies of HLA 
alleles in patients who did and did not develop ILD.
Results A total of 57 patients were treated, and 4 patients 
(7.0 %) developed ILD. The combination of HLA-B*15:01 
and DRB1*15:01 was observed in 2 of 4 patients (50 %) 
with ILD and in only 1 of 53 patients without ILD (2 %) 
resulting in odds ratio of 52.0 (95 % CI 3.2–842.5; 
p = 0.011).
Conclusion These results suggest that the combination of 
HLA-B*15:01 and DRB1*15:01 is associated with ILD in 
Japanese patients with advanced pancreatic cancer receiv-
ing gemcitabine plus erlotinib.
Keywords Erlotinib · Gemcitabine · Human leukocyte 
antigen · Interstitial lung disease · Pancreatic cancer
Introduction
In a phase III study, gemcitabine plus erlotinib improved 
overall survival significantly compared with gemcitabine 
alone in patients with advanced pancreatic cancer [1]. As 
single agents, gemcitabine and erlotinib cause intersti-
tial lung disease (ILD), which may be life threatening. A 
higher incidence of ILD was reported in Japanese patients 
compared to white patients treated with either erlotinib or 
gemcitabine. In patients with non-small cell lung cancer, 
erlotinib treatment resulted in ILD in 4.3 % of Japanese 
patients and 2.7 % of white patients [2, 3]. Similarly, the 
incidence of ILD in patients treated with gemcitabine for 
pancreatic cancer was 2.1 % of Japanese patients and 0.4 % 
of white patients [1, 4]. In a phase III study of combina-
tion chemotherapy with gemcitabine and erlotinib for pan-
creatic cancer conducted in Canada, the incidence of ILD 
was 3.5 %, while a higher incidence of 8.5 % was reported 
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in a Japanese phase II study of the same chemotherapy 
[5]. Although the etiology of gemcitabine plus erlotinib-
induced ILD is unclear, the higher incidence of ILD in 
Japanese cancer patients suggests an interethnic difference.
Risk factors for ILD identified in a post-marketing sur-
veillance study of erlotinib plus gemcitabine (POLARIS) 
in Japanese pancreatic cancer patients were the number of 
metastatic sites at >3 [hazard ratio (HR) 4.2 (95 % CI 2.2–
8.2)] and concurrent/previous lung diseases [HR 2.2 (95 % 
CI 1.1–4.5)] [6]. In a phase IV surveillance study of erlo-
tinib (POLARSTAR) as a single agent in Japanese patients 
with non-small cell lung cancer, concurrent/previous 
ILD [HR 3.2 (95 % CI 2.4–4.3)], emphysema or chronic 
obstructive pulmonary disease [HR 1.9 (95 % CI 1.4–2.4)], 
lung infection [HR 1.6 (95 % CI 1.1–2.2)], smoking history 
[HR 2.3 (95 % CI 1.7–3.0)], and period from initial can-
cer diagnosis to the start of the treatment [<360 days; HR 
0.6 (95 % CI 0.5–0.7)] were associated with ILD [2]. For 
gemcitabine, prior thoracic radiotherapy [HR 26.3 (95 % 
CI 3.4–202.1)] and pre-existing pulmonary fibrosis [HR 
6.5 (95 % CI 1.1–38.1)] were identified as significant risk 
factors for developing ILD in Japanese patients with non-
small cell lung cancer and pancreatic cancer [7].
The factors described above do not explain the higher 
incidence of ILD in Japanese patients treated with gemcit-
abine, erlotinib, or their combination compared to that of 
white patients. However, genetic factors may explain the 
observed interethnic difference in ILD. A genome-wide 
linkage study identified the mucin (MUC) 5B gene as asso-
ciated with familial interstitial pneumonia and idiopathic 
pulmonary fibrosis (IPF) in a white population [8], while an 
association between the MUC4 gene and ILD induced by 
epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKI) or acute exacerbation of IPF was reported in 
Japanese patients [9]. A few previous studies also reported 
the association between human leukocyte antigen (HLA) 
alleles and IPF or drug hypersensitivity [10–16]. How-
ever, a relationship between HLA alleles and anticancer 
drug-induced ILD has not been elucidated. To elucidate 
genetic backgrounds correlated with a higher incidence of 
ILD by gemcitabine and erlotinib in Japanese patients, we 
conducted a prospective study to analyze the association 
between HLA alleles and ILD in patients with advanced 
pancreatic cancer receiving gemcitabine plus erlotinib.
Patients and methods
Patients
Patients (20–80 years old) with histological or cytologi-
cal evidence of unresectable locally advanced or meta-
static pancreatic cancer were enrolled. Other eligibility 
criteria included an Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) of 0–1, adequate hema-
tologic, renal, and hepatic functions, and a life expectancy 
of at least 2 months. Patients with a concurrent or previ-
ous history of ILD, IPF, pneumoconiosis, drug-induced 
pneumonia, pulmonary emphysema, or chronic obstruc-
tive pulmonary disease were excluded. Patients treated 
with radiation to the chest or lung resection, as well as 
gemcitabine or EGFR-TKI within 3 months, were also 
excluded.
Study design and treatment
Patients were treated with gemcitabine (1000 mg/m2 by 
intravenous infusion for 30 min on days 1, 8, and 15 every 
4 weeks) and erlotinib (given orally at 100 mg/day) [1]. 
The treatment continued until disease progression, unac-
ceptable toxicities, or refusal by patients. This study was 
approved by the Institutional Review Boards of Kobe Uni-
versity Hospital, Kobe City Medical Center General Hospi-
tal, and National Institute of Health Sciences. All patients 
provided written informed consent.
Samples and HLA typing
Blood samples were collected from all patients within the 
2 weeks before starting the treatment. DNA for HLA typ-
ing was extracted from peripheral lymphocytes. HLA-A, B, 
and DRB1 alleles were determined using the Luminex 200 
system (Luminex, Austin, TX, USA) and WAKFlow HLA 
typing kit (Wakunaga, Hiroshima, Japan). Data were ana-
lyzed using WAKFlow typing software (Wakunaga, Hiro-
shima, Japan) in the HLA Foundation Laboratory (Kyoto, 
Japan) [17].
Assessments
Chest X-ray was performed weekly for the first 4 weeks 
and every 2 weeks thereafter. Chest computed tomogra-
phy (CT) scan was performed every 4 weeks. Antitumor 
efficacy was evaluated by CT every 8 weeks based on the 
Response Evaluation Criteria in Solid Tumors (RECIST), 
version 1.1. Adverse events were assessed using Common 
Terminology Criteria for Adverse Events (CTCAE), ver-
sion 4.0.
Statistical analysis
Statistical analyses were performed using SPSS software 
version 21.0. Allele frequencies of HLA in patients with or 
without ILD were compared using Fisher’s exact test with 
2 × 2 tables. P values <0.05 were considered statistically 
significant.
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We considered that at least 4 ILD events were necessary 
for the association study. In a Japanese phase II study of 
gemcitabine plus erlotinib for pancreatic cancer, the inci-
dence of ILD was 8.5 %; therefore, the original planned 
sample size was approximately 50 to detect 4 ILD events.
Results
Between February 2013 and July 2015, 57 patients were 
enrolled from two institutions: Kobe University Hospital 
(n = 44) and Kobe City Medical Center General Hospital 
(n = 13). Of these patients, 4 patients (7.0 %) developed 
ILD. Baseline characteristics are shown in Table 1. Median 
age and smoking history were similar between the two 
groups.
The median duration of the treatment was 1.7 months 
(range 1.0–3.3) in patients who developed ILD and 2.7 
(0.1–16.0) months in those without ILD. The most com-
mon reason for discontinuation was disease progression (45 
patients, 78.9 %) evaluated by RECIST criteria. Treatment-
related adverse events lead to treatment discontinuation in 
7 patients (12.3 %) due to malaise, diarrhea, dysgeusia, and 
ILD (4 patients, 7.0 %). Treatment was discontinued due 
to adverse events not related to the treatment in 4 patients 
(7.0 %). One patient (1.8 %) stopped the treatment due to 
progressive symptoms of the primary disease.
Median progression-free survival was 2.8 (1.0–3.5) 
months in patients with ILD and 2.8 (0.1–16.8) months in 
patients without ILD. Partial responses were achieved in 2 
patients (3.5 %), and stable disease (SD) was observed in 
27 patients (47.4 %). Best response in four patients who 
developed ILD was SD in 1 and disease progression in 3 
patients.
Chest CT scans of 4 patients who developed ILD at the 
onset of ILD are shown in Fig. 1. ILD developed at 4, 6, 
8, and 12 weeks after the start of the treatment in the 4 
patients, respectively. ILD was asymptomatic in 1 patient 
(grade 1), while it was associated with mild symptoms 
including productive cough, dyspnea, or fever in 3 patients 
(grade 2). ILD was improved by treatment discontinuation 
in all patients.
In HLA analysis, 2 of 4 patients who developed ILD 
harbored HLA-B*15:01, B*40:06, DRB1*09:01, and 
DRB1*15:01, but their association with ILD was not sta-
tistically significant. The frequencies of HLA alleles in 
patients with or without ILD are listed in the Supplemen-
tary Table. However, the combination of HLA-B*15:01 and 
DRB1*15:01 was observed in 2 of the 4 patients (50 %) who 
developed ILD, while only 1 of 53 patients (2 %) who did not 
develop ILD harbored this combination, resulting in an odds 
ratio (OR) of 52.0 (95 % CI 3.2–842.5; p = 0.01, Table 2).
Discussion
Our results demonstrate that the combination of HLA-
B*15:01 and DRB1*15:01 is over-represented significantly 
in Japanese patients with advanced pancreatic cancer who 
developed ILD after the treatment with gemcitabine plus 
erlotinib. Although the number of patients was small, the 
OR of 52.0 was much higher than the OR (2.2–4.2) of pre-
viously reported risk factors for ILD caused by gemcitabine 
and erlotinib [6].
An over‑representation of HLA-DRB1*15:01 was 
reported in white patients with IPF not associated with 
drug therapy [10]. IPF is a clinical form of ILD and the 
most common type of ILD. Other HLA types (HLA-
A*3, B*14, B*15, or B*40, and combination of A2B15, 
A2B40, A11B15, A24B58, or A30B40) were also associ-
ated with IPF in a Han Chinese population [11]. Therefore, 
Table 1  Baseline characteristics
ILD interstitial lung disease, ECOG PS Eastern Cooperative Oncol-








 Median 67 65 66
 Range 64–76 25–80 25–80
Age group—no. (%)
 <60 years 0 (0) 9 (17) 9 (16)
 ≥60 years 4 (100) 44 (83) 48 (84)
Sex—no. (%)
 Female 2 (50) 26 (49) 28 (49)
 Male 2 (50) 27 (51) 29 (51)
ECOG PS—no. (%)
 0 2 (50) 8 (15) 10 (18)
 1 2 (50) 45 (85) 47 (82)
Smoking history—no. (%)
 Never smoker 2 (50) 25 (47) 27 (47)
 Ex-smoker 2 (50) 24 (45) 26 (46)
 Current smoker 0 (0) 4 (8) 4 (7)
Extent of disease—no. (%)
 Metastatic 3 (75) 32 (60) 35 (61)
 Locally advanced 1 (25) 21 (40) 22 (39)
Site of metastatic disease—no. (%)
 Lung 1 (25) 8 (15) 9 (16)
 Liver 3 (75) 21 (40) 23 (40)
 Peritoneum 0 (0) 14 (26) 14 (25)
 Other 0 (0) 1 (2) 1 (2)
Number of metastatic site—no. (%)
 <3 4 (100) 51 (96) 55 (96)
 ≥3 0 (0) 2 (4) 2 (4)
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drug-induced ILD may be associated with certain types of 
HLA.
HLA alleles are associated with drug hypersensitiv-
ity. Carbamazepine-induced Stevens–Johnson syndrome 
is associated with HLA-B*15:02 in Chinese patients and 
HLA-A*31:01 in Japanese or European patients [12–14]. 
HLA-B*58:01 and HLA-B*57:01 are over-represented in 
allopurinol-induced severe cutaneous reactions [15] and 
abacavir hypersensitivity [16], respectively. Among anti-
cancer drugs, hepatotoxicity by lapatinib is associated with 
HLA-DQA1*02:01 or DRB1*07:01 [18]. The frequencies 
of these alleles are 10–15 % in white patients and 0.3–
0.8 % in Japanese patients [17, 19].
With regard to drug-induced ILD, HLA-A*31:01 and 
HLA-DRB1*15:02 are known to be associated with meth-
otrexate-induced ILD in Japanese patients with rheumatoid 
arthritis (RA), which induce ILD as a complication [20, 
21], and DRB1*15 and *16 were associated with a risk of 
ILD in Japanese RA patients regardless of methotrexate 
treatment [22].
These observations suggest that HLA plays an important 
role in drug-induced ILD, and our findings demonstrate 
a significant association of certain HLA types with drug-
induced ILD. The mechanism of the association between 
HLA and ILD is still unclear, although an in vitro study 
demonstrated that a direct interaction between HLA and 
carbamazepine activates T cells [23]. Drugs or their metab-
olites may act as haptens and non-covalently bind to the 
HLA molecule [24].
The incidence of ILD by gemcitabine plus erlotinib for 
advanced pancreatic cancer was 8.5 % in a Japanese phase 
II study, 6.2 % in a post-marketing surveillance study, 
and 7.0 % in our study. We carefully excluded patients 
with risk factors for ILD from our study. Nonetheless, a 
significant number of patients developed ILD. These inci-
dences are obviously higher than those reported in white 
patients. In our prospective study, an association between 
drug-induced ILD and HLA-B*15:01/DRB1*15:01 was 
observed. Differences in the population frequency of the 
HLA alleles may explain, at least in part, the interethnic 
differences in the incidence of ILD induced by gemcit-
abine and erlotinib.
In conclusion, these results suggest that the combina-
tion of HLA-B*15:01 and DRB1*15:01 is associated with 
Fig. 1  a Chest CT scans of a 65-year-old female non-smoker with 
lung and liver metastases at 8 weeks. b Chest CT scans of a 64-year-
old female non-smoker with locally advanced cancer at 12 weeks. c 
Chest CT scans of a 76-year-old male ex-smoker with lung metastasis 
at 4 weeks. d Chest CT scans of a 70-year-old male ex-smoker with 
liver metastasis at 6 weeks
◂
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ILD in Japanese patients with advanced pancreatic cancer 
receiving gemcitabine plus erlotinib.
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